Perinatal EvidenceCompass
Prepopulated workbenchMED-031

Antidepressants — tricyclic/tetracyclic

Doxepin (low-dose insomnia)

Insomnia treatment; pharmacologically lower-dose formulation than antidepressant use

Brand / product examples: Silenor

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Doxepin (low-dose insomnia)
Entity type
single-ingredient drug
Active component(s)
Doxepin
Formulation / route / interval
Oral tablet, 3 mg or 6 mg at bedtime
Attachment entry
Doxepin — low-dose insomnia use
Separate monograph status
Yes — distinguish dose/formulation and indication
Identity and cross-reference
Same active molecule as antidepressant-dose doxepin; not a duplicate formulation
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

5 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

A-001Provisional public source

ACOG recommends against withholding or discontinuing a psychiatric medication solely because of pregnancy or lactation.

Public-source certainty descriptor
guideline recommendation; not a formal GRADE rating in this module
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
preconception through lactation
Comparator
continuation versus withholding/discontinuation
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Requires individualized benefit-risk assessment and does not mean every medicine should continue.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-017Provisional public source

Long clinical experience has not established a consistent class-wide major-malformation pattern for tricyclic/tetracyclic antidepressants, but modern molecule-specific adjusted evidence is sparse and maternal anticholinergic, cardiac, overdose, and neonatal effects remain important.

Public-source certainty descriptor
low-to-moderate by molecule; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and late gestation
Comparator
exposed versus background and disease comparators
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Legacy evidence is heterogeneous; class evidence does not resolve rare agents; dose and indication vary.

Sources, citation controls, and verification state

Linked sources

PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-018Provisional public source

Doxepin is a poor lactation choice because published reports include probable serious infant toxicity, including respiratory depression or near-apnea, poor feeding, hypotonia, and marked sedation.

Public-source certainty descriptor
low for incidence but clinically important signal; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
lactation
Comparator
no exposed comparator
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Very small number of reports; cannot quantify incidence; applies to the active moiety across dose formulations.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-067Provisional public source

FDA prescription labeling uses narrative Pregnancy and Lactation Labeling Rule sections rather than the former A/B/C/D/X letter categories.

Public-source certainty descriptor
high for US regulatory framework
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
not applicable
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Exact labeling and revision date remain product-specific; non-US systems differ.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-070Provisional public source

Routine pre-delivery taper of an effective antidepressant to prevent neonatal adaptation is not recommended; it may precipitate relapse and does not eliminate exposure.

Public-source certainty descriptor
guideline-consistent position; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
late pregnancy and delivery
Comparator
continuation versus routine taper
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Direct randomized taper evidence is limited; individual toxicity or patient preference can still justify a supervised change.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending